Trial of Epinephrine and Albuterol in Bronchiolitis
Information source: Kern Medical Center
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bronchiolitis
Intervention: Epinephrine (Drug); albuterol (salbutamol) (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Kern Medical Center Official(s) and/or principal investigator(s): Paul Walsh, Paul Walsh, MD MSc(peds), Principal Investigator, Affiliation: Kern Medical Center, David Geffen School of Medicine, UCLA Paul Walsh, Principal Investigator, Affiliation: Research Director, Emergency Medicine
Summary
The purpose of this study is to see which of the two most common drugs used to treat
bronchiolitis works better. A child's participation in this study is expected to last less
than 4 hours. Approximately 600 patients will be recruited to participate in this study at
Kern Medical Center (KMC).
Bronchiolitis is a very common lung infection in babies. There are many drugs used to treat
this disease but nobody knows which one, if any, works the best. Two of the most commonly
used drugs are albuterol and epinephrine. These are both drugs given during breathing
treatments with oxygen and a mask. We are doing this study to see which of these drugs works
better or if they are both equally good. The study works as follows: after the consent
process the baby gets three treatments.
- Nebulizer 1 (Treatment)
- Treatment + 30 minutes (approximately) Nebulizer 2
- Treatment + 60 minutes (approximately) Nebulizer 3
- Treatment + 120 minutes (approximately)
The baby will be reevaluated and either discharged home or revert to standard therapy. If
the baby is discharged directly from the emergency department (E. D.), we will call you in
three days time to see how he/she is doing.
Clinical Details
Official title: Randomized Controlled Trial of Epinephrine and Albuterol in Bronchiolitis
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: Successful hospital discharge at three days
Secondary outcome: Improvement in severity of disease scoreImprovement in respiratory status
Detailed description:
Double blind RCT. Primary outcome measure is admission defined as actual admission or
discharge with unscheduled return leading to admission within 72 hours. Secondary endpoints
include change in severity of illness and response of respiratory parameters to treatment.
Eligibility
Minimum age: N/A.
Maximum age: 18 Months.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- A clinical diagnosis of bronchiolitis
Exclusion Criteria:
- Age greater than 18 months
- Disease too mild to warrant any treatment
- Emergent intubation on arrival at the ED
- Participation within another study within 30 days
- Refusal of informed parental consent
Locations and Contacts
Kern Medical Center, Bakersfield, California 93312, United States
Additional Information
Research assistant site for this study. Restricted access. Website of the Emergency Department conducting this study
Related publications: Walsh P, Rothenberg SJ, O'Doherty S, Hoey H, Healy R. A validated clinical model to predict the need for admission and length of stay in children with acute bronchiolitis. Eur J Emerg Med. 2004 Oct;11(5):265-72.
Starting date: November 2003
Ending date: May 2006
Last updated: January 23, 2008
|